Abstract: Silicone hydrogel ophthalmic devices, such as ocular inserts and contact lenses, formed in direct contact with molds comprising at least one vinyl alcohol copolymer and related methods are described. The at least one vinyl alcohol copolymer of the molds is a vinyl alcohol copolymer other than an ethylene-vinyl alcohol copolymer. The methods of manufacturing ophthalmic devices can use dry or wet demolding processes, or dry or wet delensing processes.

Abstract: Technologies are provided in example embodiments for intercepting a packet being multicast from a first tunnel endpoint in a network, determining first address mapping information of the first tunnel endpoint and a first host, wherein the first host created the packet, generating a control protocol message with the first address mapping information, and communicating the control protocol message through a control plane in the network. In more specific example embodiments, the communicating the control protocol message includes sending the control protocol message to a network repository, where the first address mapping information is registered in the network repository. In other more specific example embodiments, the communicating the control protocol message includes pushing the control protocol message to one or more other tunnel endpoints. Further embodiments include decapsulating the packet to determine an endpoint identifier of the first host and a location of the first tunnel endpoint.

Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.

Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.

Abstract: Methods for manufacturing ophthalmic devices and apparatus for treatment of ophthalmic devices are provided. The apparatus includes a tank, liquid, baffle and ophthalmic devices. The methods include placing the liquid, baffle and ophthalmic devices in a tank including at least one element which produces bubbles and/or convection currents. The baffle is structured and/or positioned to prevent bubbles from contacting the ophthalmic devices in the tank, to reduce the force of the convection currents, or both.

Abstract: The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R1, R2, Ar?, A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.

Abstract: Technologies are provided in example embodiments for intercepting a packet being multicast from a first tunnel endpoint in a network, determining first address mapping information of the first tunnel endpoint and a first host, wherein the first host created the packet, generating a control protocol message with the first address mapping information, and communicating the control protocol message through a control plane in the network. In more specific example embodiments, the communicating the control protocol message includes sending the control protocol message to a network repository, where the first address mapping information is registered in the network repository. In other more specific example embodiments, the communicating the control protocol message includes pushing the control protocol message to one or more other tunnel endpoints. Further embodiments include decapsulating the packet to determine an endpoint identifier of the first host and a location of the first tunnel endpoint.

Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists Formula (I).

Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract: A three-wheeled vehicle that includes: a single front wheel; two rear wheels; a passenger cabin; an electronic steering control unit; and a steering input device configured to send an electronic signal to the electronic steering control unit corresponding to an input received at the steering input device associated with turning the three-wheeled vehicle; wherein the electronic steering control unit is configured to counter-steer the front wheel in response to receiving the electronic signal, wherein the counter-steering of the front wheel initiates a leaning of the passenger cabin a direction of turning of the three-wheeled vehicle.

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways disease.

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

Abstract: A three-wheeled vehicle that includes: a single front wheel; two rear wheels; a passenger cabin; an electronic steering control unit; and a steering input device configured to send an electronic signal to the electronic steering control unit corresponding to an input received at the steering input device associated with turning the three-wheeled vehicle; wherein the electronic steering control unit is configured to counter-steer the front wheel in response to receiving the electronic signal, wherein the counter-steering of the front wheel initiates a leaning of the passenger cabin a direction of turning of the three-wheeled vehicle.

Abstract: Ophthalmic lens molds made from one or more thermoplastic polymer having a low level of UV light transmittance (UV % T) ophthalmic lenses including silicone hydrogel contact lenses molded using these thermoplastic polymer having low UV % T, and methods of manufacturing ophthalmic lenses by cast molding a polymerizable composition in mold members formed of these thermoplastic polymers having low UV % T and curing the polymerizable composition using UV light are described.